299 related articles for article (PubMed ID: 28629479)
21. 21-Gene recurrence score and locoregional recurrence in lymph node-negative, estrogen receptor-positive breast cancer.
Turashvili G; Chou JF; Brogi E; Morrow M; Dickler M; Norton L; Hudis C; Wen HY
Breast Cancer Res Treat; 2017 Nov; 166(1):69-76. PubMed ID: 28702894
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
Sanpaolo P; Barbieri V; Genovesi D
Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
[TBL] [Abstract][Full Text] [Related]
23. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
24. Oncotype DX in Bilateral Synchronous Primary Invasive Breast Cancer.
Karsten M; Stempel M; Radosa J; Patil S; King TA
Ann Surg Oncol; 2016 Feb; 23(2):471-6. PubMed ID: 26340863
[TBL] [Abstract][Full Text] [Related]
25. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
26. Outcomes in patients with early-stage breast cancer who underwent a 21-gene expression assay.
Barcenas CH; Raghavendra A; Sinha AK; Syed MP; Hsu L; Patangan MG; Chavez-MacGregor M; Shen Y; Hortobagyi GH; Valero V; Giordano SH; Ueno NT; Tripathy D
Cancer; 2017 Jul; 123(13):2422-2431. PubMed ID: 28199747
[TBL] [Abstract][Full Text] [Related]
27. Outcomes According to Breast Cancer Subtype in Patients Treated With Accelerated Partial Breast Irradiation.
Wilkinson JB; Shah C; Amin M; Nadeau L; Shaitelman SF; Chen PY; Grills IS; Martinez AA; Mitchell CK; Wallace MF; Vicini FA
Clin Breast Cancer; 2017 Feb; 17(1):55-60. PubMed ID: 27666436
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological implications of Tiam1 overexpression in invasive ductal carcinoma of the breast.
Li Z; Liu Q; Piao J; Hua F; Wang J; Jin G; Lin Z; Zhang Y
BMC Cancer; 2016 Aug; 16(1):681. PubMed ID: 27562113
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
[TBL] [Abstract][Full Text] [Related]
30. Numb protein expression correlates with a basal-like phenotype and cancer stem cell markers in primary breast cancer.
Rennstam K; McMichael N; Berglund P; Honeth G; Hegardt C; Rydén L; Luts L; Bendahl PO; Hedenfalk I
Breast Cancer Res Treat; 2010 Jul; 122(2):315-24. PubMed ID: 19795205
[TBL] [Abstract][Full Text] [Related]
31. Association between HER2 germline mutation A270S and prognosis in patients with primary breast cancer.
Si P; Xu Y; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
Cancer Biomark; 2018; 23(2):165-171. PubMed ID: 30175972
[TBL] [Abstract][Full Text] [Related]
32. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
[TBL] [Abstract][Full Text] [Related]
33. Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics.
Liu X; Zheng Y; Qiao C; Qv F; Wang J; Ding B; Sun Y; Wang Y
Diagn Pathol; 2015 May; 10():50. PubMed ID: 25956130
[TBL] [Abstract][Full Text] [Related]
34. High survivin mRNA expression is a predictor of poor prognosis in breast cancer: a comparative study at the mRNA and protein level.
Xu C; Yamamoto-Ibusuki M; Yamamoto Y; Yamamoto S; Fujiwara S; Murakami K; Okumura Y; Yamaguchi L; Fujiki Y; Iwase H
Breast Cancer; 2014 Jul; 21(4):482-90. PubMed ID: 22968628
[TBL] [Abstract][Full Text] [Related]
35. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis.
Turashvili G; Brogi E; Morrow M; Hudis C; Dickler M; Norton L; Wen HY
Breast Cancer Res Treat; 2017 Aug; 165(1):65-76. PubMed ID: 28577081
[TBL] [Abstract][Full Text] [Related]
36. Predictive factors on outcomes in metaplastic breast cancer.
Leyrer CM; Berriochoa CA; Agrawal S; Donaldson A; Calhoun BC; Shah C; Stewart R; Moore HCF; Tendulkar RD
Breast Cancer Res Treat; 2017 Oct; 165(3):499-504. PubMed ID: 28689362
[TBL] [Abstract][Full Text] [Related]
37. Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers.
Wernicke AG; Varma S; Greenwood EA; Christos PJ; Chao KS; Liu H; Bander NH; Shin SJ
APMIS; 2014 Jun; 122(6):482-9. PubMed ID: 24304465
[TBL] [Abstract][Full Text] [Related]
38. Differences in subtype distribution between screen-detected and symptomatic invasive breast cancer and their impact on survival.
Kobayashi N; Hikichi M; Ushimado K; Sugioka A; Kiriyama Y; Kuroda M; Utsumi T
Clin Transl Oncol; 2017 Oct; 19(10):1232-1240. PubMed ID: 28409323
[TBL] [Abstract][Full Text] [Related]
39. Predictive value of CD44 and CD24 for prognosis and chemotherapy response in invasive breast ductal carcinoma.
Chen Y; Song J; Jiang Y; Yu C; Ma Z
Int J Clin Exp Pathol; 2015; 8(9):11287-95. PubMed ID: 26617852
[TBL] [Abstract][Full Text] [Related]
40. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
